Skip to main content
OpenTrials
Completed

NCT Number: NCT04841226

Randomized Study of Silq Urinary Catheter

To assess the ability of the Silq ClearTract™ 100% Silicone 2-Way Foley Catheter to reduce biofilm formation in subjects that require a long-term indwelling Foley catheter when compared to other commercially available urinary catheters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Urology Associates of Southern Arizona, Tucson, Arizona, United States

Loading trial locations.

About this study

A prospective, randomized, multi-center, post-market study in subjects that require a long-term indwelling Foley catheter.

A randomly assigned catheter will be inserted using standard techniques. Non-surgical subjects will rate the level of pain associated with the insertion procedure using the visual analog scale (VAS). A urine sample will be collected immediately after catheter insertion, in order to generate a baseline urinalysis and urine culture.

Follow-up visits will be performed on Day 28, or upon catheter removal, whichever occurs first. The catheter will be removed on Day 28 or earlier if clinically indicated. The removed catheter will be processed and sent to the core laboratory for analysis. Urine will be collected immediately prior to catheter removal in order to conduct urinalysis and urine culture. Subject will rate level of pain associated with the removal procedure using the VAS. The subject will also fill out a questionnaire about their experience with the catheterization immediately after catheter removal. Subjects will then be exited from the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female age ≥ 18 years old;
  • Requiring indwelling 16Fr Foley catheter for at least 7 days;
  • Able and willing to comply with study procedure; and,
  • Able and willing to give informed consent.

Exclusion criteria

  • Allergy or sensitivity to any catheter materials used in this study;
  • Known urethral stricture which, in the opinion of the investigator, could influence the subject's evaluation of the catheter;
  • Planned Prophylactic use of antibiotics for CAUTI or any other infection beyond day 1 of the study (catheter implantation);
  • Symptomatic UTI being treated with antibiotics (as determined by the study PI, including at least one of the following: fever, chills, headache, burning sensation, burning of urethra or genital area, blood in urine, foul smelling urine and ≥ 10,000 cfu/mL);
  • Any other infection being treated with antibiotics at the time of catheter implantation;
  • Subjects requiring bladder irrigation during the study (an active voiding trial in surgical subjects prior to catheter removal is allowed);
  • Currently enrolled in another interventional clinical trial;
  • Any other condition that, in the opinion of the investigator, precludes study participation or poses a significant hazard in case of study participation; and
  • Females who are pregnant or breastfeeding or who plan to become pregnant during the study.

Treatment and study plan

Long-term indwelling Foley catheter

Device

Foley Catheter inserted for up to 28-days

Primary outcomes

  1. Biofilm formation

    Time frame: 5 to 7 days

    A core lab will use the BacTiter-Glo Microbial Cell Viability Assay, a well characterized method for quantifying active biomass and biofilm, to determine biofilm formation on explanted catheter samples.

Sponsors and collaborators

Lead sponsor

Silq Technologies Corporation

Industry

Registry information

Official study title

Prospective, Multi-Center, Randomized Study to Assess the Ability of the Silq ClearTract™ Urinary Catheter to Reduce Biofilm Formation When Compared to Two Types of Commercially Available Foley Catheters (Silver-Coated Latex and Silicone-coated Latex)

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Apr 12, 2021
Registry last updated
Nov 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.